MEDIA RELEASE PR36948
Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with
inVentiv Health
PETERSBURG, Va., Nov. 5 /PRNewswire-AsiaNet/ --
Star Scientific, Inc. (Nasdaq: STSI) announced today that the company plans to introduce the CigRx(TM)
nutraceutical product developed by its subsidiary, Rock Creek Pharmaceuticals, for worldwide marketing and
sales in partnership with inVentiv Health, Inc. (Nasdaq: VTIV). inVentiv Health offers a complete range of
commercialization solutions for every stage of the product lifecycle, in a range of healthcare categories that
includes nutraceutical products. The company has marketing and sales capabilities in 40 countries around the
globe. Jonnie R. Williams, Star's CEO, stated, "Cigarette smoking is the leading cause of preventable death in
the world. However, the global cigarette business, which now exceeds $300 billion, continues to grow. Our
goal is to make CigRx(TM) available to adult smokers worldwide who wish to maintain a nicotine-free
metabolism." Rock Creek Pharmaceuticals will be responsible for the manufacturing of CigRx(TM), and the
company anticipates that inVentiv Health will be involved in the product marketing and sales, with a focus on
product education for physicians and health care professionals, as well as consumers.
Star also announced that it has retained McColl Partners LLC to advise the company on a range of
corporate finance matters, including the assessment of strategic initiatives involving new products. McColl
Partners, an independent investment banking firm co-founded by Hugh McColl, former Chairman of Bank of
America, specializes in the needs of management and owners of middle-market companies. The firm offers
strategic advice and assistance to its clients regarding mergers and acquisitions.
This press release contains certain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Star Scientific, Inc. and its consolidated subsidiaries (collectively, the
"Company") has tried, whenever possible, to identify these forward-looking statements using words such as
"anticipates", "believes", "estimates", "expects", "plans", "intends" and similar expressions. These statements
reflect the Company's current beliefs and are based upon information currently available to it. Accordingly,
such forward-looking statements involve known and unknown risks, uncertainties and other factors which
could cause the Company's actual results, performance or achievements to differ materially from those
expressed in, or implied by, such statements. These risks, uncertainties and contingencies include, without
limitation, the challenges inherent in new product development initiatives, the uncertainties inherent in the
progress of scientific research, the Company's ability to raise additional capital in the future necessary to
maintain its business, potential disputes concerning the Company's intellectual property, risks associated with
litigation regarding such intellectual property, potential delays in obtaining any necessary government
approvals of the Company's low-TSNA tobacco products, market acceptance of the Company's new
smokeless tobacco products, competition from companies with greater resources than the Company, the
Company's decision not to join the Master Settlement Agreement ("MSA"), the effect of state statutes adopted
under the MSA, and the Company's dependence on key employees and on its strategic relationships with
Brown & Williamson Tobacco Corporation in light of its combination with RJ Reynolds Tobacco Company, Inc.
The impact of potential litigation, if initiated against or by individual states that have adopted the MSA, could
be materially adverse to the Company.
Although the Company believes the expectations reflected in such forward-looking statements are based on
reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation
will not be material. See additional discussion under "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2008, as filed with the SEC on March 16, 2009, and other factors
detailed from time to time in the Company's other filings with the SEC, available at www.sec.gov. This
information is current as of this date. The Company undertakes no obligation to update or advise upon any
such forward-looking statements to reflect events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events.
About Rock Creek Pharmaceuticals
Rock Creek Pharmaceuticals develops pharmaceutical products for treatment of addiction and other
neurological disorders, and other products such asnutraceuticals. The company supports third-party
academic, educational and therapeutic advances in both these areas of research. Rock Creek has
scientific and research offices in Gloucester, MA and a regulatory office in Washington, DC.
About Star Scientific
Star Scientific is a technology-oriented tobacco company with a toxin reduction mission. It is engaged in the
development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins (principally
tobacco specific nitrosamines, or TSNAs), through the utilization of the innovative StarCured(R) tobacco
curing technology, and in sublicensing that technology to others. Star Scientific has a Corporate and Sales
Office in Petersburg, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and
manufacturing facilities in Chase City, VA. For more information, visit
About inVentiv Health
inVentiv Health, Inc. (Nasdaq: VTIV) is an insights-driven global healthcare leader that provides dynamic
solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing
and communications solutions through its four core business segments: inVentiv Clinical, inVentiv
Communications, inVentiv Commercial, and inventive Patient Outcomes. inVentiv Health's client roster is
comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor
companies, including all top 20 global pharmaceutical manufacturers. For more information, visit
Contact:
Sara Troy Machir
VP, Communications & Investor Relations
Star Scientific, Inc.
301-654-8300
SOURCE: Star Scientific, Inc.
CONTACT: Sara Troy Machir,
VP, Communications & Investor Relations,
+1-301-654-8300
NEWS 
